# US 6,391,314 B1 · Porcine circoviruses vaccines diagnostic reagents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,391,314 B1
- Document ID: US6391314B1
- Status: Granted
- Kind: B1
- Application number: 09/161,092
- Filed: 1998-09-25
- Granted: 2002-05-21
- Earliest claimed: 1997-10-03
- Assignees: Merial Limited; The Queen's University of Belfast; University of Saskatchewan
- Inventors: Gordon Allan; Brian Meehan; Edward Clark; John Ellis; Deborah Haines; Lori Hassard; John Harding; Catherine Elisabeth Charreyre; Gilles Emile Chappuis; Francis McNeilly
- Web page: https://patentgrep.com/patent/US6391314B1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/51: {comprising whole cells, viruses or DNA/RNA}
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/16043: viral genome or elements thereof as genetic vector
- C12N 2710/24043: viral genome or elements thereof as genetic vector
- C12N 2750/10021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2750/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2750/10043: viral genome or elements thereof as genetic vector
- C12N 2750/10063: by chemical treatment
- C12N 2750/10064: by serial passage
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to new porcine circovirus strains isolated from pulmonary or ganglionic samples obtained from farms affected by the post-weaning multisystemic wasting syndrome (PMWS). It relates to purified preparations of these strains, conventional attenuated or inactivated vaccines, recombinant live vaccines, plasmid vaccines and subunit vaccines, as well as reagents and diagnostic methods. It also relates to the DNA fragments which can be used for the production of subunits in an in vitro expression vector or as sequences to be integrated into a virus or plasmid type in vivo expression vector.

## Claims

### Claim 1

An immunogenic composition comprising a vector that contains and expresses in vivo in a porcine host cell, a nucleic acid molecule or fragment thereof encoding a type II porcine circovirus antigen and a pharmaceutically acceptable vehicle or diluent.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, wherein the vector is a viral vector.

### Claim 3 (depends on 1)

The immunogenic composition of claim 1, wherein the vector is a plasmid.

### Claim 4 (depends on 1)

The immunogenic composition of claim 1, wherein the composition induces an immunological response in a porcine host against type II porcine circovirus.

### Claim 5 (depends on 1)

The immunogenic composition according to claim 1, further comprising an additional antigen of another porcine pathogen or a nucleic acid molecule that expresses the additional antigen of another porcine pathogen.

### Claim 6 (depends on 5)

The immunogenic composition according to claim 5, wherein the additional antigen is from a porcine pathogen selected from the group consisting of porcine reproductive and respiratory syndrome (PRRS), Mycoplasma hyopneumoniae, Actinobacillus pleuropneumoniae, E. coli, porcine Atrophic Rhinitis, Aujeszky disease, Hog cholera and Swine Influenza.

### Claim 7 (depends on 5)

The immunogenic composition according to claim 5, wherein the additional antigen is from PRRS.

### Claim 8 (depends on 5)

The immunogenic composition according to claim 5, wherein the additional antigen is from PRRS and Mycoplasma hyopneumoniae.

### Claim 9 (depends on 1)

The immunogenic composition according to claim 1, comprising an antigen of a first type II porcine circovirus strain, or a nucleic acid molecule that expresses the antigen, and an antigen of a second strain of type II porcine circovirus, or a nucleic acid molecule that expresses that antigen, wherein at least one of the first and second antigens is the vector that contains and expresses in vivo in a porcine host cell, a nucleic acid molecule or fragments thereof encoding a type II porcine circovirus antigen.

### Claim 10 (depends on 9)

The immunogenic composition according to claim 9, wherein the first antigen is a porcine circovirus antigen selected from the group consisting of an inactivated porcine circovirus, a live attenuated porcine circovirus, and a sub-unit of a porcine circovirus, and the second antigen is the vector that contains and expresses in vivo in a porcine host cell, a nucleic acid molecule or fragment thereof encoding a type II porcine circovirus antigen.

### Claim 11 (depends on 1)

The immunogenic composition according to claim 1, further comprising an adjuvant.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method for inducing an immunological response against a porcine circovirus comprising administering to a porcine the immunogenic composition of any one of claims 1-11.
